BIOLASE TECHNOLOGY INC Form 8-K May 11, 2011

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 10, 2011

BIOLASE TECHNOLOGY, INC.

(Exact name of registrant as specified in its charter)

Delaware 000-19627 87-0442441

(State or other Jurisdiction of (Commission File Number) (IRS Employer Identification No.)

Incorporation)

4 Cromwell

Irvine, California92618(Address of Principal Executive Offices)(Zip Code)

Registrant's telephone number, including area code: (949) 361-1200

Not Applicable

(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure.

On May 10, 2011, Federico Pignatelli, Chairman and Chief Executive Officer of Biolase Technology, Inc. (the "Company"), and Frederick D. Furry, Chief Financial Officer of the Company, will deliver a presentation at the 2nd Annual Bright Lights Conference that will include a written communication comprised of slides. The slides from the presentation are attached hereto as Exhibit 99.1, and are hereby incorporated by reference.

A copy of the slides will be available for viewing and download at http://www.biolase.com/investors for a period of 30 days.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

99.1 Presentation material from the 2nd Annual Bright Lights Conference, dated May 10, 2011.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIOLASE TECHNOLOGY, INC.

Date: May 10, 2011

By: <u>/s/ Federico Pignatelli</u>

Federico Pignatelli

Chairman and Chief Executive Officer

3

Exhibit Index

Exhibit No. Description

99.1 Presentation material from the 2nd Annual Bright Lights Conference, dated May 10, 2011.

4